- recruitingPHASE2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
This study is testing a new oral medicine, APL-101, for people with advanced cancers. It focuses on lung cancer and other solid tumours where specific genetic changes linked to a protein called MET are found. Researchers want to see how well it works and if it's safe.
United States · Australia · Canada - recruitingPHASE2
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
This study looks at a drug called crizotinib for advanced lung cancer where specific gene changes (ROS1 or MET) are found. It aims to see how well the drug works in these patients.
Canada